Drug companies are facing one of the most volatile operating environments in years.
Ongoing conflict in the Middle East, rising raw material costs and mounting price concessions are squeezing margins across the sector, with the UK government's price concessions currently running 120% higher than they were in April 2025.
If instability continues, raw material costs look set to climb further, putting pressure on manufacturers and distributors to find new ways to control costs and streamline operations.
At the same time, pharmacies across the UK are already reporting widespread shortages of common drugs such as Aspirin.
In an industry in which missing inventory can threaten batch integrity and, in the worst cases, lead to the destruction of sensitive medicines, there is little room for error.
Against this backdrop, supply chain resilience has moved from being a back-office concern to a board-level priority.
Not yet a Subscriber?
This is a small extract of the full article which is available ONLY to premium content subscribers. Click below to get premium content on Manufacturing Chemist.
Subscribe now Already a subscriber? Sign in here.
